Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 224 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urticaria Clear all
Completed Phase 4 Interventional Results available

Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

NCT01457430
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Icatibant
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Wheaton, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 1 Interventional

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

NCT06050928
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Oral EP262
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
Tampa, Florida • Boise, Idaho • Owensboro, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 4, 2026, 6:51 PM EDT
Recruiting No phase listed Observational

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

NCT07408219
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 4, 2026, 6:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)

NCT02974595
View directory record Official record
Conditions
NOMID, DIRA, NLRC4-MAS, SAVI, CANDLE
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 99 Years
Enrollment
3,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

NCT00292981
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 Esterase Inhibitor
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
6 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
13
States / cities
Weston, Florida • Atlanta, Georgia • Idaho Falls, Idaho + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

NCT01359969
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
rhC1INH
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
2 Years to 13 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 4, 2026, 6:51 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

NCT04583007
View directory record Official record
Conditions
Hereditary Angioedema (HAE), Angioedema
Interventions
Lanadelumab 150 mg, Lanadelumab 300 mg
Drug
Lead sponsor
Shire
Industry
Eligibility
2 Years and older
U.S. locations
14
States / cities
Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 1 Interventional

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

NCT04538794
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
CDX-0159, Normal Saline
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Gilbert, Arizona • Sarasota, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 1 Interventional Results available

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

NCT02093923
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
San Diego, California • Walnut Creek, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

NCT02586805
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
31
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 4, 2026, 6:51 PM EDT
Recruiting Phase 3 Interventional

Donidalorsen Treatment in Children With Hereditary Angioedema

NCT07298447
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
Donidalorsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Santa Monica, California • Miami, Florida • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 4, 2026, 6:51 PM EDT
Available No phase listed Expanded access

Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

NCT07216378
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Sebetralstat
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
2 Years to 11 Years
U.S. locations
6
States / cities
San Diego, California • Evansville, Indiana • Wheaton, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)

NCT00456508
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

NCT00912093
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
39
States / cities
Alabaster, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

NCT00462709
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
C1 esterase inhibitor [human] (C1INH-nf)
Biological
Lead sponsor
Shire
Industry
Eligibility
1 Year and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
48
States / cities
Hoover, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 4, 2026, 6:51 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Role of Circulating Innate Lymphoid Cells in Allergic Disorders

NCT03069495
View directory record Official record
Conditions
Allergy, Asthma, Urticaria
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

NCT00628108
View directory record Official record
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine 1.25 mg, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
6 Months to 11 Months
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 4, 2026, 6:51 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Donidalorsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
16
States / cities
Paradise Valley, Arizona • La Jolla, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 3 Interventional

Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

NCT06343779
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III
Interventions
Deucrictibant, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
12 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II

NCT06467084
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900 150 mg, KVD900 300 mg, KVD900 600 mg
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
2 Years to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema

NCT05695248
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Navenibart
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 4, 2026, 6:51 PM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

NCT05024058
View directory record Official record
Conditions
Chronic Inducible Urticaria
Interventions
Ligelizumab, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Evansville, Indiana • North Charleston, South Carolina • El Paso, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 4, 2026, 6:51 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

NCT00890162
View directory record Official record
Conditions
Anaphylaxis, Hypotension, Bronchospasm, Angioedema
Interventions
Epinephrine, Omalizumab (Xolair), Placebos
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2019 · Synced Sep 4, 2026, 6:51 PM EDT
Recruiting Phase 3 Interventional

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

NCT06361537
View directory record Official record
Conditions
Acute Hereditary Angio Edema
Interventions
OCTA-C1-INH, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
2 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 4, 2026, 6:51 PM EDT